Aurion Biotech develops regenerative cell therapies to treat blindness and vision loss caused by corneal endothelial disease. Their lead program, AURN001, uses donor endothelial cells to replace dysfunctional cells, aiming to restore corneal clarity without relying solely on traditional donor transplantation. The company focuses on scalable manufacturing and quality testing to expand global access to advanced ophthalmology treatments.

CorneaGen provides high-quality corneal transplant tissue and patient-specific laser-cut tissue inlays, gamma-irradiated for sterility and stability, to enhance vision and comfort for patients with corneal disease. The company also develops specialized surgical instruments, such as the EndoSerter®-PL and Geuder Pre-Loaded Glass Cannula, to improve surgical outcomes for ophthalmologists.

Iantrek develops microinterventional surgical technologies, including the CycloPen™ and AlloFlo™, designed for precise cyclodialysis and enhanced uveoscleral outflow in glaucoma treatment. These systems address the challenges of traditional glaucoma surgeries by providing controlled, minimally invasive options that improve patient outcomes and reduce recovery times.

Orasis Pharmaceuticals develops QLOSI™, an ophthalmic eye drop formulation designed to treat presbyopia, a condition that causes blurred near vision due to the aging of the eye's crystalline lens. This product aims to enhance visual acuity for over 128 million people in the U.S. affected by this progressive condition.

Develops a topical small molecule treatment that reactivates dormant hair follicle stem cells by targeting a unique metabolic switch, restoring the body’s natural hair growth capacity. This approach addresses hair loss conditions like androgenetic alopecia, offering a non-invasive alternative to existing therapies with limited efficacy and invasive procedures.

Re-Vana Therapeutics develops biodegradable ocular implants using patented photo-crosslinked technology for sustained intraocular release of biologics and small-molecule drugs over six months. This approach addresses the need for reduced frequency of drug administration in patients with sight-threatening diseases, enhancing treatment adherence and patient outcomes.

Sydnexis is developing a patented topical eyedrop formulation designed to reduce the progression of pediatric myopia with a once-daily application at bedtime. The company is currently conducting a Phase 3 study to evaluate the efficacy of this treatment in children.

Tarsus Pharmaceuticals develops targeted therapies for diseases with high unmet medical needs, including the first FDA-approved treatment for Demodex blepharitis, XDEMVY® (lotilaner ophthalmic solution) 0.25%. The company is advancing a robust pipeline of investigational treatments for conditions such as papulopustular rosacea and Lyme disease, addressing significant gaps in available therapies.

The startup develops ophthalmic drug candidates specifically targeting glaucoma, utilizing advanced medication delivery systems to enhance patient safety and adherence. Their approach aims to transform established eye medications into effective therapies, paving the way for future applications across various ocular conditions.